Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from The Cancer Genome Atlas

References

1. 1.↵
   2. Coons SW,
   3. Johnson PC,
   4. Scheithauer BW, et al

   . Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997;79:1381–93 doi:10.1002/(SICI)1097-0142(19970401)79:7<1381::AID-CNCR16>3.0.CO%3B2-W pmid:9083161

   CrossRefPubMedWeb of Science
2. 2.↵
   2. van den Bent MJ

   . Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. Acta Neuropathol 2010;120:297–304 doi:10.1007/s00401-010-0725-7 pmid:20644945

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Brat DJ,
   3. Verhaak RG,
   4. Aldape KD, et al

   Cancer Genome Atlas Research Network; Brat DJ, Verhaak RG, Aldape KD, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015;372:2481–98 doi:10.1056/NEJMoa1402121 pmid:26061751

   CrossRefPubMed
4. 4.↵
   2. Louis DN,
   3. Perry A,
   4. Reifenberger G, et al

   . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016;131:803–20 doi:10.1007/s00401-016-1545-1 pmid:27157931

   CrossRefPubMed
5. 5.↵
   2. Vigneswaran K,
   3. Neill S,
   4. Hadjipanayis CG

   . Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification. Ann Transl Med 2015;3:95 doi:10.3978/j.issn.2305-5839.2015.03.57 pmid:26015937

   CrossRefPubMed
6. 6.↵
   2. Turkalp Z,
   3. Karamchandani J,
   4. Das S

   . IDH mutation in glioma: new insights and promises for the future. JAMA Neurol 2014;71:1319–25 doi:10.1001/jamaneurol.2014.1205 pmid:25155243

   CrossRefPubMed
7. 7.↵
   2. Patel SH,
   3. Poisson LM,
   4. Brat DJ, et al

   . T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower grade gliomas: a TCGA/TCIA project. Clin Cancer Res 2017;23:6078–85 doi:10.1158/1078-0432.CCR-17-0560 pmid:28751449

   Abstract/FREE Full Text
8. 8.↵
   2. Wang YY,
   3. Wang K,
   4. Li SW, et al

   . Patterns of tumor contrast enhancement predict the prognosis of anaplastic gliomas with IDH1 mutation. AJNR Am J Neuroradiol 2015;36:2023–29 doi:10.3174/ajnr.A4407 pmid:26316565

   Abstract/FREE Full Text
9. 9.↵
   2. Natsumeda M,
   3. Igarashi H,
   4. Nomura T, et al

   . Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-Tesla magnetic resonance spectroscopy. Acta Neuropathol Commun 2014;2:158 doi:10.1186/s40478-014-0158-y pmid:25376594

   CrossRefPubMed
10. 10.↵
    2. Kickingereder P,
    3. Sahm F,
    4. Radbruch A, et al

    . IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Sci Rep 2015;5:16238 doi:10.1038/srep16238 pmid:26538165

    CrossRefPubMed
11. 11.↵
    2. Gupta RK,
    3. Cloughesy TF,
    4. Sinha U, et al

    . Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. J Neurooncol 2000;50:215–26 doi:10.1023/A:1006431120031 pmid:11263501

    CrossRefPubMed
12. 12.↵
    2. Yamasaki F,
    3. Kurisu K,
    4. Satoh K, et al

    . Apparent diffusion coefficient of human brain tumors at MR imaging. Radiology 2005;235:985–91 doi:10.1148/radiol.2353031338 pmid:15833979

    CrossRefPubMedWeb of Science
13. 13.↵
    2. Lee EJ,
    3. Lee SK,
    4. Agid R, et al

    . Preoperative grading of presumptive low-grade astrocytomas on MR imaging: diagnostic value of minimum apparent diffusion coefficient. AJNR Am J Neuroradiol 2008;29:1872–77 doi:10.3174/ajnr.A1254 pmid:18719036

    Abstract/FREE Full Text
14. 14.↵
    2. Hilario A,
    3. Ramos A,
    4. Perez-Nuñez A, et al

    . The added value of apparent diffusion coefficient to cerebral blood volume in the preoperative grading of diffuse gliomas. AJNR Am J Neuroradiol 2012;33:701–07 doi:10.3174/ajnr.A2846 pmid:22207304

    Abstract/FREE Full Text
15. 15.↵
    2. Zhang L,
    3. Min Z,
    4. Tang M, et al

    . The utility of diffusion MRI with quantitative ADC measurements for differentiating high-grade from low-grade cerebral gliomas: evidence from a meta-analysis. J Neurol Sci 2017;373:9–15 doi:10.1016/j.jns.2016.12.008 pmid:28131237

    CrossRefPubMed
16. 16.↵
    TCGA-GBM collection from The Cancer Imaging Archive (TCIA). https://wiki.cancerimagingarchive.net/display/Public/TCGA-GBM. Accessed April 01, 2016.
17. 17.↵
    TCGA-LGG collection from The Cancer Imaging Archive (TCIA). https://wiki.cancerimagingarchive.net/display/Public/TCGA-LGG. Accessed April 01, 2016.
18. 18.↵
    2. Clark K,
    3. Vendt B,
    4. Smith K, et al

    . The Cancer Imaging Archive (TCIA): maintaining and operating a public information repository. J Digit Imaging 2013;26:1045–57 doi:10.1007/s10278-013-9622-7 pmid:23884657

    CrossRefPubMedWeb of Science
19. 19.↵
    Wiki for the VASARI feature set The National Cancer Institute Web site. https://wikicancerimagingarchivenet/display/Public/VASARI+Research+Project. . Updated July 25, 2016
20. 20.↵
    2. Eckel-Passow JE,
    3. Lachance DH,
    4. Molinaro AM, et al

    . Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 2015;372:2499–508 doi:10.1056/NEJMoa1407279 pmid:26061753

    CrossRefPubMed
21. 21.↵
    2. Xiong J,
    3. Tan W,
    4. Wen J, et al

    . Combination of diffusion tensor imaging and conventional MRI correlates with isocitrate dehydrogenase 1/2 mutations but not 1p/19q genotyping in oligodendroglial tumours. Eur Radiol 2016;26:1705–15 doi:10.1007/s00330-015-4025-4 pmid:26396108

    CrossRefPubMed
22. 22.↵
    2. Leu K,
    3. Ott GA,
    4. Lai A, et al

    . Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas. J Neurooncol 2017;134:177–88 doi:10.1007/s11060-017-2506-9 pmid:28547590

    CrossRefPubMed
23. 23.↵
    2. Murakami R,
    3. Hirai T,
    4. Kitajima M, et al

    . Magnetic resonance imaging of pilocytic astrocytomas: usefulness of the minimum apparent diffusion coefficient (ADC) value for differentiation from high-grade gliomas. Acta Radiol 2008;49:462–67 doi:10.1080/02841850801918555 pmid:18415792

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Higano S,
    3. Yun X,
    4. Kumabe T, et al

    . Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 2006;241:839–46 doi:10.1148/radiol.2413051276 pmid:17032910

    CrossRefPubMedWeb of Science
25. 25.↵
    2. Murakami R,
    3. Sugahara T,
    4. Nakamura H, et al

    . Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging. Radiology 2007;243:493–99 doi:10.1148/radiol.2432060450 pmid:17356177

    CrossRefPubMedWeb of Science
26. 26.↵
    2. Yamasaki F,
    3. Sugiyama K,
    4. Ohtaki M, et al

    . Glioblastoma treated with postoperative radio-chemotherapy: prognostic value of apparent diffusion coefficient at MR imaging. Eur J Radiol 2010;73:532–37 doi:10.1016/j.ejrad.2009.01.013 pmid:19250783

    CrossRefPubMed
27. 27.↵
    2. Zulfiqar M,
    3. Yousem DM,
    4. Lai H

    . ADC values and prognosis of malignant astrocytomas: does lower ADC predict a worse prognosis independent of grade of tumor? A meta-analysis. AJR Am J Roentgenology 2013;200:624–29 doi:10.2214/AJR.12.8679 pmid:23436853

    CrossRefPubMed
28. 28.↵
    2. Sugahara T,
    3. Korogi Y,
    4. Kochi M, et al

    . Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999;9:53–60 doi:10.1002/(SICI)1522-2586(199901)9:1<53::AID-JMRI7>3.0.CO%3B2-2 pmid:10030650

    CrossRefPubMedWeb of Science
29. 29.↵
    2. Wasserman JK,
    3. Nicholas G,
    4. Yaworski R, et al

    . Radiological and pathological features associated with IDH1–R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours. PLoS One 2015;10:e0123890 doi:10.1371/journal.pone.0123890 pmid:25849605

    CrossRefPubMed
30. 30.↵
    2. Tan WL,
    3. Huang WY,
    4. Yin B, et al

    . Can diffusion tensor imaging noninvasively detect IDH1 gene mutations in astrogliomas? A retrospective study of 112 cases. AJNR Am J Neuroradiol 2014;35:920–27 doi:10.3174/ajnr.A3803 pmid:24557705

    Abstract/FREE Full Text
31. 31.↵
    2. Jiao Y,
    3. Killela PJ,
    4. Reitman ZJ, et al

    . Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 2012;3:709–22 doi:10.18632/oncotarget.588 pmid:22869205

    CrossRefPubMedWeb of Science
32. 32.↵
    2. Ceccarelli M,
    3. Barthel FP,
    4. Malta TM, et al

    . Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 2016;164:550–63 doi:10.1016/j.cell.2015.12.028 pmid:26824661

    CrossRefPubMed
33. 33.↵
    2. Lam WW,
    3. Poon WS,
    4. Metreweli C

    . Diffusion MR imaging in glioma: does it have any role in the pre-operation determination of grading of glioma? Clin Radiol 2002;57:219–25 doi:10.1053/crad.2001.0741 pmid:11952318

    CrossRefPubMed
34. 34.↵
    2. Murakami R,
    3. Hirai T,
    4. Sugahara T, et al

    . Grading astrocytic tumors by using apparent diffusion coefficient parameters: superiority of a one- versus two-parameter pilot method. Radiology 2009;251:838–45 doi:10.1148/radiol.2513080899 pmid:19318585

    CrossRefPubMedWeb of Science
35. 35.↵
    2. Khayal IS,
    3. Vandenberg SR,
    4. Smith KJ, et al

    . MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas. Neuro Oncol 2011;13:1192–201 doi:10.1093/neuonc/nor122 pmid:21865401

    CrossRefPubMed
36. 36.↵
    2. Kang Y,
    3. Choi SH,
    4. Kim YJ, et al

    . Gliomas: histogram analysis of apparent diffusion coefficient maps with standard- or high-b-value diffusion-weighted MR imaging–correlation with tumor grade. Radiology 2011;261:882–90 doi:10.1148/radiol.11110686 pmid:21969667

    CrossRefPubMedWeb of Science
37. 37.↵
    2. Kitis O,
    3. Altay H,
    4. Calli C, et al

    . Minimum apparent diffusion coefficients in the evaluation of brain tumors. Eur J Radiol 2005;55:393–400 pmid:16129247

    CrossRefPubMed
38. 38.↵
    2. Olar A,
    3. Wani KM,
    4. Alfaro-Munoz KD, et al

    . IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol 2015;129:585–96 doi:10.1007/s00401-015-1398-z pmid:25701198

    CrossRefPubMed
39. 39.↵
    2. Reuss DE,
    3. Mamatjan Y,
    4. Schrimpf D, et al

    . IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol 2015;129:867–73 doi:10.1007/s00401-015-1438-8 pmid:25962792

    CrossRefPubMed
40. 40.↵
    2. Khayal IS,
    3. McKnight TR,
    4. McGue C, et al

    . Apparent diffusion coefficient and fractional anisotropy of newly diagnosed grade II gliomas. NMR Biomed 2009;22:449–55 doi:10.1002/nbm.1357 pmid:19125391

    CrossRefPubMedWeb of Science
41. 41.↵
    2. Johnson DR,
    3. Diehn FE,
    4. Giannini C, et al

    . Genetically defined oligodendroglioma is characterized by indistinct tumor borders at MRI. AJNR Am J Neuroradiol 2017;38:678–84 doi:10.3174/ajnr.A5070 pmid:28126746

    Abstract/FREE Full Text